An Old Transplant Drug Shows Promise in Slowing Type 1 Diabetes Progression

New research suggests that a low dose of an inexpensive, decades-old immune-suppressing medication can delay the progression of type 1 diabetes when given shortly after diagnosis. The drug appears effective with fewer side effects than higher doses used in previous studies.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

A drug called polyclonal antithymocyte globulin (ATG), already used safely in transplant surgery for decades, can slow the loss of insulin-producing beta cells in the pancreas
A much smaller dose of ATG is nearly as effective as higher doses tested before, but with fewer unwanted effects
The treatment works best when given soon after type 1 diabetes diagnosis, during a window called the 'honeymoon phase' when some beta cells still produce insulin
Because ATG is inexpensive and already approved for medical use, it may be more accessible than newer therapies

What Happens in Type 1 Diabetes

Type 1 diabetes occurs when the immune system mistakenly attacks and destroys beta cells in the pancreas. These beta cells are responsible for producing insulin, the hormone that allows glucose from food to enter cells for energy. Without enough insulin, glucose builds up in the bloodstream instead of being used by the body.

A Critical Window After Diagnosis

Soon after someone is diagnosed with type 1 diabetes, there is a period—often called the 'honeymoon phase'—when beta cells have not yet been completely destroyed. During this time, the pancreas can still produce some insulin on its own. Research suggests this is an important window of opportunity to intervene and protect the remaining beta cells from further immune attack.

How the Study Points to a New Approach

Earlier research showed that ATG, an immune-suppressing drug used in transplant surgery for decades, could reduce the loss of beta cells when given at high doses. The new research demonstrates that a much smaller dose achieves nearly the same benefit while causing fewer side effects.

Because ATG is an older, inexpensive medication already approved for medical use, it may offer a more accessible option for people newly diagnosed with type 1 diabetes compared to newer, costlier therapies.

What This Means

This research adds to growing evidence that acting quickly after type 1 diagnosis—during the honeymoon phase—may help preserve remaining beta cell function. However, more research is needed to understand the long-term effects, optimal dosing, and how this approach fits into comprehensive diabetes management. As always, treatment decisions should be made in consultation with your healthcare team.

Evidence label

Origin: livescience.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.